In the Claims

Please cancel claims 111-113 and amend claims 100, 117 and 123 under the provisions of proposed 37 C.F.R. §1.121, as set forth in the Official Gazette on February 25, 2003.

76. (Previously added) A compound having the structure:



wherein R_1 is 3-hydroxy cyclopentyl ethylamino carbonylamino propyl, N,N-diethylamino carbonylamino ethyl, thioacetamido ethyl, 3-amino acetyloxy cyclopentyl, 3-hydroxy cyclopentyl, 2-pyrrolyl carbonyl aminoethyl, 2-imidazolidinone ethyl, 1-aminocarbonyl-2-methyl propyl, 1-aminocarbonyl-2-phenyl ethyl, 3-hydroxy azetidino, 2-imidazolyl ethyl, acetamido ethyl, 1-(R)-phenyl-2-hydroxyethyl, or N-methylaminocarbonyl pyridyl-2- methyl;

wherein R_5 and R_6 are independently H, substituted or unsubstituted alkyl, or aryl.

77. (Previously added) The compound of claim 76, having the structure:



78. (Previously added) The compound of claim 76, having the structure:



79. (Previously added) The compound of claim 76, having the structure:



80. (Previously added) The compound of claim 76, having the structure:



81. (Previously added) The compound of claim 76, having the structure:



82. (Previously added) The compound of claim 76, having the structure:



83. (Previously added) The compound of claim 82, having the structure:



84. (Previously added) The compound of claim 82, having the structure:



85. (Previously added) The compound of claim 82, having the structure:



86. (Previously added) The compound of claim 82, having the structure:



87. (Previously added) The compound of claim 76, having the structure:



88. (Previously added) The compound of claim 76, having the structure:



89. (Previously added) The compound of claim 76, having the structure:



90. (Previously added) The compound of claim 76, having the structure:



91. (Previously added) The compound of claim 76, having the structure:



92. (Previously added) The compound of claim 76, having the structure:



93. (Previously added) The compound of claim 92, having the structure:



94. (Previously added) The compound of claim 76, having the structure:



95. (Previously added) The compound of claim 94, having the structure:



96. (Previously added) The compound of claim 76, having the structure:



97. (Previously added) The compound of claim 96, having the structure:



98. (Previously added) The compound of claim 96, having the structure:



99. (Previously added) A compound having the structure:



100. (Currently amended) A method for treating a disease associated with an A3 adenosine receptor in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the compound of claim 76 or 99 so as to thereby treat the disease associated with the A3 adenosine receptor in the subject, wherein the disease associated with the A3 adenosine receptor is ~~cardiac hypoxia, cerebral ischemia, diuresis,~~ myocardial ischemia, bronchitis, or bronchoconstriction ~~or diabetes~~.

101. (Previously added) The method of claim 100, wherein the subject is a mammal.

102. (Previously added) The method of claim 101, wherein the mammal is a human.

103. (Previously added) A prodrug of the compound of claim 76 or

99, wherein the prodrug is metabolized *in vivo* by a human subject to an active drug which selectively inhibits the A3 adenosine receptor wherein the prodrug is

an ester of an alcohol or carboxylic acid group, if such a group is present in the compound;

an acetal or ketal of an alcohol group, if such a group is present in the compound;

an N-Mannich base or an imine of an amine group, if such a group is present in the compound; or

a Schiff base, oxime, acetal, enol ester, oxazolidine, or thiazolidine of a carbonyl group, if such a group is present in the compound.

104. (Previously added) The prodrug of claim 103, wherein the prodrug is water-soluble.

105. (Previously added) The prodrug of claim 103, wherein said prodrug is metabolized *in vivo* by esterase catalyzed hydrolysis.

106. (Previously added) A pharmaceutical composition comprising the prodrug of claim 103 and a pharmaceutically acceptable carrier.

107. (Previously added) The pharmaceutical composition of claim 106, wherein said pharmaceutical composition is an ophthalmic formulation.

108. (Previously added) The pharmaceutical composition of claim 106, wherein said pharmaceutical composition is an periocular, retrobulbar or intraocular injection formulation.

109. (Previously added) The pharmaceutical composition of claim 106, wherein said pharmaceutical composition is a systemic formulation.

110. (Previously added) A method for inhibiting the activity of an A3 adenosine receptor in a cell that is subjected to abnormal stimulation of the A3 adenosine receptor, which comprises contacting the cell with a compound of claim 76 or 99, so as to inhibit the activity of the A3 adenosine receptor.

Claims 111-113 (Canceled)

114. (Previously added) A method for treating a respiratory disorder associated with an A3 adenosine receptor in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the compound of claim 76 or 99, so as to thereby treat the respiratory disorder in the subject, wherein the respiratory disorder is asthma, chronic obstructive pulmonary disease, allergic rhinitis or an upper respiratory disorder.

115. (Previously added) The method of claim 114, wherein the subject is a human.

116. (Previously added) A method for treating inflammation of the eye associated with an A3 adenosine receptor in a subject in need of such treatment, which comprises administering to the subject a therapeutically effective amount of the compound of claim 76 or 99 so as to thereby treat the inflammation of the eye in the subject.

117. (Currently amended) A method for treating a disease

associated with an A3 adenosine receptor in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of claim 76 or 99 so as to thereby treat the disease associated with the A3 adenosine receptor in the subject, wherein the disease associated with the A3 adenosine receptor is associated with mast cell degranulation ~~or eosinophil activity~~.

118. (Previously added) The method of claim 117 wherein the subject is human.

119. (Previously added) A method for treating a disease associated with an A3 adenosine receptor in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of claim 76 or 99 so as to thereby treat the disease associated with the A3 adenosine receptor in the subject, wherein the disease associated with the A3 adenosine receptor is asthma, glaucoma, retinopathy, ocular ischemia, or macular degeneration.

120. (Previously added) The method of claim 119, wherein the subject is human.

121. (Previously added) The method of claim 119, wherein the disease is asthma.

122. (Previously added) The method of claim 119, wherein the disease is glaucoma.

123. (Currently amended) A combination therapy for glaucoma, comprising the compound of claim 76 or 99, and a prostaglandin agonist, ~~b2~~ β2 agonist, or a muniscrinic

antagonist.

124. (Previously added) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 76 or 99 and a pharmaceutically acceptable carrier.

125. (Previously added) The pharmaceutical composition of claim 124, wherein said therapeutically effective amount is effective to treat a respiratory disorder or a gastrointestinal disorder.

126. (Previously added) The pharmaceutical composition of claim 125, wherein said gastrointestinal disorder is diarrhea.

127. (Previously added) The pharmaceutical composition of claim 125, wherein said respiratory disorder is asthma, allergic rhinitis, or chronic obstructive pulmonary disease.

128. (Previously added) The pharmaceutical composition of claim 124, wherein said pharmaceutical composition is an ophthalmic formulation.

129. (Previously added) The pharmaceutical composition of claim 124, wherein said pharmaceutical composition is an periocular, retrobulbar or intraocular injection formulation.

130. (Previously added) The pharmaceutical composition of claim 124, wherein said pharmaceutical composition is a systemic formulation.

131. (Previously added) The pharmaceutical composition of claim 124, wherein said pharmaceutical composition is a surgical irrigating solution.

132. (Previously added) A packaged pharmaceutical composition for treating a disease associated with A3 adenosine receptor in a subject, comprising:

(a) a container holding a therapeutically effective amount of the compound of claim 76 or 99; and

(b) instructions for using said compound for treating said disease in a subject.

133. (Previously added) A method of preparing the compound of claim 76, comprising the steps of

a) reacting  and 

to provide 

wherein P is a removable protecting group;

b) treating the product of step a) under cyclization conditions to provide

 ;

c) treating the product of step b) under suitable conditions to provide

 ; and

d) treating the chlorinated product of step c) with NH2R1 to provide



wherein R_1 is 3-hydroxy cyclopentyl ethylamino carbonylamino propyl, N,N-diethylamino carbonylamino ethyl, thioacetamido ethyl, 3-amino acetyloxy cyclopentyl, 3-hydroxy cyclopentyl, 2-pyrrolyl carbonyl aminoethyl, 2-imidazolidinone ethyl, 1-aminocarbonyl-2-methyl propyl, 1-aminocarbonyl-2-phenyl ethyl, 3-hydroxy azetidino, 2-imidazolyl ethyl, acetamido ethyl, 1-(R)-phenyl-2-hydroxyethyl, or N-methylaminocarbonyl pyridyl-2- methyl;

wherein R_5 and R_6 are independently H, substituted or unsubstituted alkyl, or aryl.